# ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

Source: https://onco.cc/trials/nct00261313/  
OnCo record `nct00261313` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pegfilgrastim and Darbepoetin alfa in Breast cancer, run by Amgen, completed.

## Summary

ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer is a phase 2 interventional study registered as NCT00261313 by Amgen, with 80 participants recorded, started 2005-12 and reaching its primary completion in 2007-06. Interventions recorded: Neulasta, Aranesp. Conditions recorded: Breast Cancer.

Linked to the drug Darbepoetin alfa because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00261313
- Phase: 2
- Setting: An Open Label Phase 2 Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel Delivered Every 14 Days With Pegfilgrastim and Darbepoetin Alfa Support for the Adjuvant Treatment of Women With Breast Cancer
- Sponsor: Amgen
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT00261313: https://clinicaltrials.gov/study/NCT00261313

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Darbepoetin alfa](https://onco.cc/drugs/darbepoetin-alfa/), [Pegfilgrastim](https://onco.cc/drugs/pegfilgrastim/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct00261313.json